title: NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.
abstract: The non-steroidal anti-inflammatory drug flurbiprofen is a selective amyloid lowering agent which has been studied clinically in Alzheimer's disease. HCT-1026 is an ester prodrug of flurbiprofen incorporating a nitrate carrier moiety that in vivo provides NO bioactivity and an improved safety profile. In vitro, HCT-1026 retained the cyclooxygenase inhibitory and non-steroidal anti-inflammatory drug activity of flurbiprofen, but at concentrations at which levels of amyloid-beta 1-42 amino acid were lowered by flurbiprofen, amyloid-beta 1-42 amino acid levels were elevated 200% by HCT-1026. Conversely, at lower concentrations, HCT-1026 behaved as a selective amyloid lowering agent with greater potency than flurbiprofen. The difference in concentration-responses between flurbiprofen and HCT-1026 in vitro suggests different cellular targets; and in no case did a combination of nitrate drug with flurbiprofen provide similar actions. In vivo, HCT-1026 was observed to reverse cognitive deficits induced by scopolamine in two behavioral assays; activity that was also shown by a classical nitrate drug, but not by flurbiprofen. The ability to restore aversive memory and spatial working and reference memory after cholinergic blockade has been demonstrated by other agents that stimulate NO/cGMP signaling. These observations add positively to the preclinical profile of HCT-1026 and NO chimeras in Alzheimer's disease.
authors.affiliation: Department of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
authors.forename: Samer O
authors.initials: SO
authors.lastname: Abdul-Hay
authors.forename: Jia
authors.initials: J
authors.lastname: Luo
authors.forename: Rezene T
authors.initials: RT
authors.lastname: Ashghodom
authors.forename: Gregory R J
authors.initials: GR
authors.lastname: Thatcher
mesh_terms: D016229:Amyloid beta-Peptides / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D045744:Cell Line, Tumor; D003072:Cognition Disorders / Q000139:chemically induced* / Q000188:drug therapy; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005480:Flurbiprofen / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D047468:Immunoprecipitation / Q000379:methods; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009447:Neuroblastoma; D018696:Neuroprotective Agents / Q000494:pharmacology*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism*; D011453:Prostaglandins / Q000378:metabolism; D051381:Rats; D020318:Rats, Long-Evans; D012601:Scopolamine; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods; D013778:Tetrazolium Salts; D013844:Thiazoles; D014162:Transfection / Q000379:methods
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D008070:Lipopolysaccharides; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D011453:Prostaglandins; D013778:Tetrazolium Salts; D013844:Thiazoles; C075222:amyloid beta-protein (1-42); C095631:nitroflurbiprofen; D005480:Flurbiprofen; D012601:Scopolamine; D052247:Nitric Oxide Synthase Type II; C022616:thiazolyl blue
references.citation: Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):317-30
references.pmid: 15461866
references.citation: J Neurosci. 2002 Mar 15;22(6):2246-54
references.pmid: 11896164
references.citation: Curr Top Med Chem. 2005;5(7):707-20
references.pmid: 16101430
references.citation: Neuropsychologia. 2008 Aug;46(10):2476-84
references.pmid: 18514746
references.citation: J Pharmacol Exp Ther. 2004 May;309(2):626-33
references.pmid: 14755007
references.citation: Ann Rheum Dis. 1972 Jul;31(4):319-24
references.pmid: 4558227
references.citation: Neurology. 2008 Jun 10;70(24):2291-8
references.pmid: 18509093
references.citation: Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11285-9
references.pmid: 1684863
references.citation: Anal Biochem. 2002 Sep 1;308(1):168-77
references.pmid: 12234478
references.citation: Nature. 2001 Nov 8;414(6860):212-6
references.pmid: 11700559
references.citation: Nat Rev Drug Discov. 2008 Feb;7(2):156-67
references.pmid: 18167491
references.citation: Annu Rev Pharmacol Toxicol. 1998;38:97-120
references.pmid: 9597150
references.citation: Neurobiol Aging. 2000 May-Jun;21(3):383-421
references.pmid: 10858586
references.citation: Nature. 1999 Jul 8;400(6740):173-7
references.pmid: 10408445
references.citation: J Neurochem. 1999 Aug;73(2):532-7
references.pmid: 10428048
references.citation: Neuropsychopharmacology. 2007 Mar;32(3):505-13
references.pmid: 16525416
references.citation: Neurobiol Dis. 2006 Apr;22(1):25-32
references.pmid: 16307889
references.citation: J Clin Invest. 2003 Aug;112(3):440-9
references.pmid: 12897211
references.citation: Life Sci. 1989;45(20):1869-76
references.pmid: 2513461
references.citation: Neurology. 1997 Mar;48(3):626-32
references.pmid: 9065537
references.citation: Neurology. 2009 Jun 2;72(22):1899-905
references.pmid: 19386997
references.citation: Neurology. 1995 Jan;45(1):51-5
references.pmid: 7824134
references.citation: J Alzheimers Dis. 2004 Dec;6(6 Suppl):S75-84
references.pmid: 15665418
references.citation: Neurobiol Aging. 1999 May-Jun;20(3):305-13
references.pmid: 10588578
references.citation: Mol Pharmacol. 2008 Nov;74(5):1381-91
references.pmid: 18676677
references.citation: Neurosci Lett. 1995 Feb 24;187(1):5-8
references.pmid: 7617301
references.citation: Brain Res Brain Res Rev. 2005 Apr;48(2):370-8
references.pmid: 15850676
references.citation: Science. 2002 Jul 19;297(5580):353-6
references.pmid: 12130773
references.citation: J Neurochem. 2003 Jul;86(1):220-7
references.pmid: 12807441
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13217-21
references.pmid: 12244210
references.citation: J Neurochem. 2004 Nov;91(3):521-36
references.pmid: 15485484
references.citation: Nature. 2002 Apr 4;416(6880):535-9
references.pmid: 11932745
references.citation: Psychopharmacology (Berl). 2006 Jan;183(4):439-45
references.pmid: 16320087
references.citation: Curr Alzheimer Res. 2005 Apr;2(2):171-82
references.pmid: 15974915
references.citation: N Engl J Med. 2001 Nov 22;345(21):1515-21
references.pmid: 11794217
references.citation: Jpn J Pharmacol. 2001 Jun;86(2):230-5
references.pmid: 11459126
references.citation: Eur J Pharmacol. 2009 Jan 14;602(2-3):215-22
references.pmid: 19046964
references.citation: Neurobiol Aging. 2002 Sep-Oct;23(5):787-94
references.pmid: 12392782
references.citation: Science. 1982 Jul 30;217(4558):408-14
references.pmid: 7046051
references.citation: J Neurosci. 2005 Jul 20;25(29):6887-97
references.pmid: 16033898
references.citation: J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47
references.pmid: 10071091
references.citation: Neuroscience. 2007 Feb 9;144(3):950-60
references.pmid: 17137722
references.citation: J Neurosci. 2007 Jan 17;27(3):627-33
references.pmid: 17234594
references.citation: Eur J Pharmacol. 2002 Oct 25;453(2-3):319-24
references.pmid: 12398920
references.citation: Br J Pharmacol. 1995 Sep;116(2):1713-4
references.pmid: 8528547
references.citation: Biochem Biophys Res Commun. 1994 Dec 30;205(3):1829-35
references.pmid: 7811271
references.citation: Nature. 1986 Jun 26-Jul 2;321(6073):864-6
references.pmid: 3724846
references.citation: Curr Alzheimer Res. 2006 Jul;3(3):237-45
references.pmid: 16842101
references.citation: Proc Natl Acad Sci U S A. 1989 Nov;86(22):9030-3
references.pmid: 2573074
references.citation: Gastroenterology. 1994 Jul;107(1):173-9
references.pmid: 8020659
references.citation: Lancet Neurol. 2008 Jun;7(6):483-93
references.pmid: 18450517
references.citation: Gut. 1997 May;40(5):608-13
references.pmid: 9203938
references.citation: J Biol Chem. 2002 Aug 16;277(33):29584-92
references.pmid: 12048217
references.citation: Neurotox Res. 2007 Dec;12(4):247-62
references.pmid: 18201952
references.citation: Histol Histopathol. 1995 Apr;10(2):509-19
references.pmid: 7599445
references.citation: J Neurochem. 2002 Nov;83(4):1009-12
references.pmid: 12421374
references.citation: J Neuroimmunol. 2004 May;150(1-2):10-9
references.pmid: 15081244
references.citation: Pharm Res. 2001 Feb;18(2):151-6
references.pmid: 11405284
references.citation: J Neurosci Res. 2001 Nov 15;66(4):715-22
references.pmid: 11746392
references.citation: Neuroreport. 1997 Oct 20;8(15):3213-7
references.pmid: 9351645
references.citation: J Alzheimers Dis. 2002 Jun;4(3):193-201
references.pmid: 12226538
references.citation: Brain Res Brain Res Rev. 2005 Apr;48(2):400-8
references.pmid: 15850679
references.citation: Eur J Pharmacol. 1991 Jul 12;207(3):183-8
references.pmid: 1680060
references.citation: Eur J Pharmacol. 1989 Oct 17;172(4-5):413-6
references.pmid: 2555211
references.citation: Neuroreport. 2000 Nov 27;11(17):3883-6
references.pmid: 11117508
references.citation: J Neurochem. 2009 Nov;111(3):683-95
references.pmid: 19702658
references.citation: Brain Res. 1999 Jan 2;815(1):36-43
references.pmid: 9974120
references.citation: Eur J Pharmacol. 2006 Feb 17;532(1-2):162-9
references.pmid: 16443213
references.citation: Eur J Pharmacol. 1998 Jan 2;341(1):1-9
references.pmid: 9489849
references.citation: J Pharmacol Exp Ther. 2003 Sep;306(3):821-7
references.pmid: 12805474
references.citation: Pharmacol Biochem Behav. 2004 Dec;79(4):691-9
references.pmid: 15582676
references.citation: J Pharmacol Exp Ther. 2006 May;317(2):752-61
references.pmid: 16424150
references.citation: Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):292-9
references.pmid: 18090435